

The German Research Consortium for the Study of Bipolar Disorder (BipoLife): A Magnetic Resonance Imaging Study Protocol

Christoph Vogelbacher (✉ vogelbac@staff.uni-marburg.de)

University of Marburg: Philipps-Universität Marburg <https://orcid.org/0000-0002-3191-1400>

Jens Sommer

University of Marburg: Philipps-Universität Marburg

Verena Schuster

University of Marburg: Philipps-Universität Marburg

Miriam H. A. Bopp

University of Marburg: Philipps-Universität Marburg

Irina Falkenberg

University of Marburg: Philipps-Universität Marburg

Philipp S. Ritter

Dresden University Hospital: Universitätsklinikum Carl Gustav Carus

Felix Bempohl

Charite University Hospital Berlin: Charite Universitätsmedizin Berlin

Catherine Hindi Attar

Charite University Hospital Berlin: Charite Universitätsmedizin Berlin

Lisa Rauer

Heidelberg University

Karolin E. Einenkel

Heidelberg University

Jens Teutlein

Heidelberg University

Oliver Gruber

Heidelberg University

Georg Juckel

Ruhr-Universität Bochum

Vera Flasbeck

Ruhr-Universität Bochum

Christoph Mulert

Justus Liebig Universität Giessen

Martin Hautzinger

University of Tübingen: Eberhard Karls Universität Tübingen

Andrea Pfennig

Dresden University Hospital: Universitätsklinikum Carl Gustav Carus

Silke Matura

University of Frankfurt: Goethe-Universität Frankfurt am Main

Andreas Reif

University of Frankfurt: Goethe-Universität Frankfurt am Main

Dominik Grotegerd

WWU Münster: Westfälische Wilhelms-Universität Münster

Udo Danlowski

University of Münster: Westfälische Wilhelms-Universität Münster

Tilo Kircher

University of Marburg: Philipps-Universität Marburg

Michael Bauer

Dresden University Hospital: Universitätsklinikum Carl Gustav Carus

Andreas Jansen

University of Marburg: Philipps-Universität Marburg

Research Article

Keywords: BipoLife, Bipolar disorder, major depression, fMRI, MRI quality assurance, multicenter study, early recognition, early intervention

Posted Date: March 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-339978/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at International Journal of Bipolar Disorders on November 17th, 2021. See the published version at <https://doi.org/10.1186/s40345-021-00240-6>.

Abstract

Background: Bipolar disorder is one of the most severe mental disorders. Its chronic course is associated with high rates of morbidity and mortality, a high risk of suicide and poor social and occupational outcomes. Despite the great advances over the last decades in understanding mental disorders, the mechanisms underlying bipolar disorder at the neural network level still remain elusive. This has severe consequences for clinical practice, for instance by inadequate diagnoses or delayed treatments. The German research consortium *BipoLife* aims to shed light on the mechanisms underlying bipolar disorders. It was established in 2015 and incorporates ten university hospitals across Germany. Its research projects focus in particular on individuals at high risk of bipolar disorder, young patients in the early stages of the disease and patients with an unstable highly relapsing course and/or with acute suicidal ideation.

Methods: Functional and structural magnetic resonance imaging (MRI) data was acquired across nine sites within three different studies. Obtaining neuroimaging data in a multicenter setting requires among others the harmonization of the acquisition protocol, the standardization of paradigms and the implementation of regular quality control procedures. The present article outlines the MRI imaging protocols, the acquisition parameters, the imaging paradigms, the neuroimaging quality assessment procedures and the number of recruited subjects.

Discussion: The careful implementation of a MRI study protocol as well as the adherence to well-defined quality assessment procedures is one key benchmark in the evaluation of the overall quality of large-scale multicenter imaging studies. This article contributes to the *BipoLife* project by outlining the rationale and the design of the MRI study protocol. It helps to set the necessary standards for follow-up analyses and provides the technical details for an in-depth understanding of follow-up publications.

1. Background

Bipolar disorder (BD) is a severe, recurrent and heterogeneous mental disorder that affects more than 1% of the population worldwide. It usually has its onset during youth. Its chronic course is associated with high rates of morbidity and mortality, a high risk of suicide, and poor social and occupational outcomes, making it one of the main causes of disability among young and working-age people worldwide (Murray 1996). BD is one of the most heritable mental illnesses (McGuffin et al. 2003). Bipolar offspring are at a higher risk of developing BD than the general population (Axelson et al. 2015). There is strong evidence that the index (hypo)manic episode in both bipolar offspring and community cohorts is frequently preceded by prodromal affective or non-affective symptoms (Duffy et al. 2014). Besides the genetic predisposition, a subgroup of patients suffering from Attention Deficit Hyperactivity Disorder (ADHD), as well as patients diagnosed with a single or recurrent depression are more likely to develop BD (Duffy

2012; Pfennig et al. 2016). A first-episode BD is then followed by an unpredictable and relapsing course throughout the lifespan.

Despite the great advances over the last decades in understanding mental disorders, the mechanisms underlying BD at the cellular, transmitter and neural network level still remain elusive. This has severe consequences for clinical practice. For instance, only a subpopulation of patients, shows good responses to lithium monotherapy. Clinical characteristics alone are often not sufficient to guide an effective choice of different treatment options. Therefore, more research is, necessary for the development of individualized treatment plans. In particular individuals at high risk of BD, young patients in the early stages of the disease, and patients with an unstable highly relapsing course and/or with acute suicidal ideation have been identified as those in need (Pfennig et al. 2020; Ritter et al. 2016).

The German research consortium *BipoLife* aims to shed light on the elusive basis and causes of BD. It was established in 2015 and incorporates ten university hospitals across Germany (Berlin, Bochum, Dresden, Frankfurt, Göttingen, Hamburg, Heidelberg, Marburg, Munich and Tübingen) as well as the medical informatics section of the University of Göttingen. Its integrated multi-center approach focuses on the one hand on the prevention, diagnosis and treatment of BD, on the other hand on the identification of genomic, transcriptomic and proteomic disease markers. The major goals are the development of new diagnostic approaches and innovative therapeutic interventions as well as the translation of scientific knowledge into clinical practice. The *BipoLife* network comprises two multicenter clinical studies, a naturalistic-epidemiological study, two neuroscientific research projects and two translational platforms for the application of innovative genetic and imaging methods. The scientific knowledge gained through the projects of this consortium shall be used in the long term to improve early detection and targeted early intervention, thereby reducing the individual and socio-economical burden of BD. A detailed description of the consortium and the projects can be found in (Ritter et al. 2016).

Within the research network, magnetic resonance imaging (MRI) data were acquired in three clinical subprojects (termed “project A1”, “project A2” and “project B2” in the *BipoLife* nomenclature). The same neuroimaging protocol was used in all projects. Prior to describing the imaging protocol, however, the clinical subprojects in which, among others, collect neuroimaging data will be shortly summarized (see Ritter et al. (2016) for an extensive overview).

The aim of **project A1** (“Improving early recognition and intervention in people at-risk of developing bipolar disorder”) was to evaluate and improve early recognition and intervention strategies in individuals at increased risk for developing BDs using a naturalistic, longitudinal design. The baseline assessment was followed by biannual follow-ups for a minimum of 24 months. Three groups of individuals were studied: (1) Help-seeking adolescents and young adults aged 15-35 years without a diagnosis of BD consulting early detection centers and specialized services with ≥ 1 proposed risk factor for BD; (2) In-/outpatients with a depressive episode aged 15-35 years; (3) in-/outpatients with ADHD aged 15-35 years. Over the study period, the natural course of risk and resilience factors, early symptoms of BD, and changes in symptom severity (including the transition to BD) were observed using recently developed

psychometric testing. Participation in the neuroimaging assessments was optional for the participants, i.e., they could also participate in the clinical part of project A1 without being measured by MRI. Neuroimaging data were acquired only during the baseline assessment, not during the follow-up appointments. The imaging data will be used, for instance, to develop biomarkers to improve the prediction of transition or remission in distinct at-risk subgroups of BD. The clinical study protocol of project A1 is described in detail in (Pfennig et al. 2020).

Project A2 (“Adjuvant psychotherapy in early stage bipolar disorder”) focuses on the effects of different forms of adjuvant psychotherapies for relapse prevention in BD. This randomized controlled clinical trial aims to test the hypothesis that the addition of a specific short-term emotional-cognitive psychotherapy (“Spezifische Emotional-Kognitive Psychotherapie”, SEKT) to standard psychiatric care (treatment as usual, TAU) in comparison to a supportive, self-directed therapy (“Fördernde, Emotionsfokussierte, Supportive Psychotherapie”, FEST) will lead to positive outcomes in younger patients with BD (age 18-35 years), for instance, reduced relapse rates, missed days at work/school or days spent in hospitals. As in project A1, participation in the neuroimaging assessments was optional. Neuroimaging data were acquired at two time points, i.e. prior to and after the completion of the psychotherapeutic interventions. The imaging data will be used, for instance, to test the hypothesis that specific psychotherapy (SEKT) will have a stronger effect on neural networks associated with emotion regulation and social cognition compared to FEST (Stamm et al. 2020).

Project B2 is an add-on project for an ongoing separate multicenter, double-blind, randomized controlled trial investigating the effect of lithium in addition to TAU in affectively ill patients with acute suicidality over 5 weeks (see Lewitzka et al. (2015) for a description of the study protocol). It aims to identify neuroimaging markers that are associated with lithium treatment. Neuroimaging data were acquired at two time points, i.e. prior to and following the five-week intervention. The imaging data will be used, for instance, to develop biomarkers to predict successful anti-suicidal treatment with lithium.

Acquiring neuroimaging data from up to nine different sites (all centers except Munich) required the harmonization of the acquisition protocol, the standardization of paradigms and the implementation of regular quality control procedures to detect signal aberrations and potential MR scanner malfunctions. *BipoLife*, therefore, included a dedicated translational imaging platform (termed “TPP2” in the *BipoLife* nomenclature) to coordinate the acquisition and analysis of all neuroimaging data. In this article, the imaging protocol, the acquisition parameters, the imaging paradigms and the neuroimaging quality assessment procedures will be described in detail. This article thus summarizes the methodological background necessary to fully understand follow-up publications from the *BipoLife* consortium.

2. Methods

In the methods section, we present details on the acquired cohorts (2.1), describe the imaging paradigms and the process of data acquisition (2.2), summarize the technical imaging infrastructure and MRI data

acquisition parameters (2.3), and describe the quality assessment protocol for neuroimaging data (2.4) and data storage (2.5).

2.1 Subjects

Neuroimaging data were acquired in seven study centers in projects A1 and A2, in project B2 in four centers. Table 1 lists the study centers that were involved in each project. In project A1, participants were measured only once, i.e., during the baseline assessment. In projects A2 and B2, participants were measured twice, i.e., before and after the project-specific therapy (psychotherapy in project A2, lithium therapy in project B2). Data acquisition started in October 2015 and ended for all projects in December 2020.

Table 1: Involvement of BipolLife study centers in the neuroimaging projects A1, A2 and B2

Clinical project	Berlin (BE)	Bochum (BO)	Dresden (DR)	Frankfurt (FR)	Göttingen (GÖ)	Hamburg (HA)	Heidelberg (HE)	Marburg (MA)	Tübingen (TÜ)
A1	✓	✓	✓	✓	✗	✓	✗	✓	✓
A2	✓	✓	✓	✗	✓	✓	✗	✓	✓
B2	✗	✗	✓	✓	✓	✗	✓	✗	✗

In the following, we will describe inclusion and exclusion criteria for all subprojects. We will then present the general characteristics of the study samples.

Project A1 was a naturalistic, prospective-longitudinal observational cohort study of participants aged 15–35 years. From July 2015 until September 2018, help-seeking adolescents and young adults consulting early recognition centers presenting with at least one of the proposed risk factors for BD (group 1) and in- and outpatients with depressive syndrome (group 2) or ADHD (group 3), respectively, were recruited at the different sites. Overall, N = 2279 persons were screened for inclusion and exclusion criteria. N = 1419 participants were included in the study. Due to their baseline diagnostic status, N = 1229 risk participants were assigned to one of the three risk groups (see Pfennig et al. (2020) for a detailed description of the study cohort). All participants received the option to participate in the MRI assessments. Overall, N = 310 participants were measured with MRI (group1: n = 123; group 2: n = 146; group 3: n = 44) (Table 2).

Table 2: Project A1: Subjects' characteristics (sex, age).

310 participants were assessed with fMRI in project A1. They were assigned to one of three risk groups. The present table shows how many subjects were measured in each center (BE – Berlin, BO – Bochum, DR – Dresden, FR – Frankfurt, HA- Hamburg MA – Marburg, TÜ – Tübingen).

	BE	BO	DR	FR	HA	MA	TÜ	Total	Sex (male/female)	Mean age (+/- SD)
Group 1	39	6	32	10	4	26	6	123	63/60	24.8 (+/- 5.1)
Group 2	27	3	6	22	42	39	7	143	68/78	25.4(+/- 5.4)
Group 3	0	0	0	17	0	15	12	44	26/18	27.1 (+/- 3.9)

Project A2 was a randomized controlled clinical trial. From August 2015 until December 2019, young patients (age between 18 and 35 years) suffering from BD with at least one episode during the preceding two years were recruited different. All participants had to be in stable remission and regular medical care (including mood-stabilizing medication). Patients were randomized to one of the two psychotherapies, i.e. either SEKT or FEST (see Stamm et al. (2020) for a detailed description of the study design). All participants received the option to additionally participate in the MRI assessment before and after therapy about five months later. Overall, 66 patients were measured with MRI before the start of the therapeutic intervention and 38 patients after completion of the therapeutic intervention (Table 3). Additionally, a cohort of 35 healthy control subjects matched for age, sex, education status (as assessed by the highest graduation certificate) and handedness (as assessed by the Edinburgh handedness inventory, (Oldfield 1971)) was recruited (Table 3).

Table 3: Project A2: Subjects' characteristics (sex, age).

65 patients were assessed with MRI in project A2 before therapy (T1), 38 were assessed a second time after therapy (T2). They were randomly assigned to one of two treatment groups (i.e., either SEKT or FEST). The present table shows how many subjects were measured in each center (BE – Berlin, BO – Bochum, DR – Dresden, GÖ – Göttingen, HA – Hamburg, MA – Marburg, TÜ – Tübingen). Additionally, a group of healthy control subjects was measured.

	BE	BO	DR	GÖ	HA	MA	TÜ	Total	Sex (male/female)	Mean age (+/- SD)
Patients, T1	22	2	9	6	12	5	9	65	36/29	32.7 (+/- 9.3)
Patients, T2	15	0	7	2	5	3	6	38	21/17	32.9 (+/- 8.8)
Controls, T1	21	0	0	0	2	2	10	35	15/20	30.2 (+/- 8.6)
Controls, T2t	19	0	0	0	0	2	3	25	14/11	32.0 (+/- 9.3)

Project B2 was an add-on project for an ongoing separate multicenter, double-blind, randomized controlled trial investigating the effect of lithium (see Lewitzka et al. (2015) for a description of the study protocol). The participants received the option to participate in the MRI assessments before and after therapy five weeks later. Until the end of the project, 21 patients were included before therapy, 16 after therapy (Table 4).

Table 4: Project B2: Subjects' characteristics (sex, age).

21 patients were assessed with MRI in project B2 before therapy (T1), 16 were assessed a second time after therapy (T2). The present table shows how many subjects were measured in each center (DR – Dresden, FR – Frankfurt, GÖ – Göttingen, HE – Heidelberg).

	DR	FR	GÖ	HE	Total	Sex (male/female)	Mean age (+/- SD)
Patients, T1	19	0	1	1	21	14/7	34.0(+/- 12.1)
Patients, T2	15	0	1	0	16	11/5	35.6 (+/- 12.7)

2.2 Experimental design

After inclusion in the clinical projects A1, A2 and B2, respectively, subjects received the option to additionally participate in the MRI assessments. They were included in the MRI study if they consented and if they met typical MRI safety regulations (e.g. no pacemaker). The MRI scanning protocol consisted of a structural localizer, a T1-weighted high-resolution anatomical image, a resting-state functional MRI (fMRI) sequence, three task-based fMRI paradigms, a field map and a gel-phantom measurement for quality assessment. The resting-state took 8:24 min. Participants were asked to relax, keep their eyes open and fixate a fixation cross. The task-based paradigms assessed reward functions (“desire-reason dilemma (DRD) task”, (Diekhof et al. 2012)), emotion processing (“Hariri task”, (Dannlowski et al. 2012), and Theory-of-Mind (ToM) functions (Walter et al. 2011)). All MRI sequences were performed in the same fixed order. The MRI battery took 52 min scanning time per session (about 43 min for the measurement of the participants, 9 min for the phantom measurement). Prior to the MRI measurement, participants were introduced to each task outside the MR scanner. An overview of the study course is presented in Figure 1.

Figure 1: Study overview. Left: After inclusion in the clinical studies A1, A2 and B2, respectively, subjects received the option to additionally participate in the MRI assessments (“MRI information”). If they were eligible and consented, they were introduced to each task outside the MR scanner (“MRI training”). Right: The MRI measurement consisted of a localizer scan, a structural T1-weighted image, a resting state fMRI sequence, three task-based fMRI paradigms (DRD task, “Hariri” task and ToM task) and a field map. The DRD task was divided into two sessions.

Desire-reason dilemma (DRD) task. The DRD task used conditioned reward stimuli in different experimental situations, thereby allowing the investigation of subcortical structures of the dopaminergic

reward system and their specific functional interactions with prefrontal cortices. The paradigm has been described in detail elsewhere (Diekhof et al. 2012; Diekhof and Gruber 2010).

The DRD task consisted of two parts. The first part was an operant conditioning task that was performed outside of the MR scanner. The goal of the task was the establishment of stimulus-response-reward contingencies relevant for the second part of the experiment. Subjects learned to associate specific colors and responses with either an immediate reward or a neutral outcome. The choice between a left and a right button was free. The participants were encouraged to explore the stimulus-response-reward contingencies to maximize their overall outcome. In total, squares of eight different colors were presented twenty times each in a randomized sequence. Each square was shown until the subject pressed the response button. Two of these colors led to an immediate reward (i.e., reward of 10 points) when collected with a left button press. Four colors always led to a neutral outcome regardless of button choice. The selection of the remaining two colors with a left button press led to an immediate loss (i.e., loss of 10 points). These latter two colors were included in the conditioning task to prevent a behavioral preference for the left response button also in response to the neutral colors.

After the participant was familiarized with the colors and sufficient conditioning with reward stimuli the second part (the regular task) was performed outside the scanner to train the short reaction time. The stimulus material (i.e., rewarded and neutral colors) was the same as in the first part except for the 'potential punishment' stimuli that were not presented. In contrast to the first part, however, participants had to pursue a superordinate long-term goal during task blocks of 4 or 8 trials. They were required to acquire 50 points for a successful completion of each task block. The superordinate goal of an individual task block was to collect the two target colors that were defined at the beginning of each block. Target colors could occur more than once within a block and had to be collected upon each appearance to reach the goal. Apart from this, subjects also had to incorporate one of two context rules into their decisions, which determined how to treat the remaining non-target colors to successfully finish a block (i.e., to gain 50 points for achievement of the superordinate long-term goal). In the "reason context", all non-target colors had to be rejected regardless of their immediate reward association to achieve the superordinate goal. In the "desire context", subjects were free to also collect the two conditioned (rewarding) non-target colors for an immediate bonus, whereas all remaining unrewarded non-target colors had to be rejected. Bonuses acquired in the "desire context" were added to the 50 points at the end of a block, if the long-term goal was successfully reached. Although subjects were free to decide whether to collect or to reject conditioned (rewarding) non-targets in the "desire context", the optimal strategy for reward maximization was – apart from collecting the targets and rejecting the unrewarded non-targets – to give into the "desire" to acquire the immediately rewarded non-target colors. Conversely, during the "reason context", subjects were forced to overcome the behavioral tendency to respond to these conditioned (rewarding) stimuli, which contradicted the superordinate long-term goal. This means that in the latter case, participants had to exert self-control to resolve this "desire-reason dilemma".

In both the "desire" and the "reason context", the conditioned (rewarding) non-targets, as well as the unrewarded non-targets, could occur up to 30 times each. Goal-relevant target stimuli could appear up to

60 times each in a pseudorandomized sequence with a counterbalanced trial order. Goal failures reduced these numbers because a failure to implement the long-term goal terminated a block immediately before its actual end with the feedback “goal failure”. The consequence of such a goal failure was a loss of the points already acquired within that respective task block.

In the scanner, subjects completed 40 task blocks over the course of two fMRI runs. Half of the task blocks were performed in the “desire context”, the other half in the “reason context” (Figure 2). The context always changed after two consecutive task blocks, which was indicated by a context cue. Context cues indicating a change in decision context always appeared for 1800 ms (followed by a 200 ms blank screen delay). Subsequently, the two relevant target colors for the upcoming task block were shown for 1500 ms (preceded by a 200 ms blank screen delay and followed by another 200 ms, in which a blank screen was presented). The relevant target colors changed every task block. The display of the two relevant target colors was followed by individual trials, in which subjects had to collect relevant targets and also bonuses in the “desire context” or only had to collect targets in the “reason context”. An individual trial had a duration of 1900 ms. It started with a grey blank screen (duration = 200 ms) before a colored square was shown for 900 ms, which was followed by immediate feedback for the current choice the subject had made. This feedback had a duration of 700 ms. A trial ended with a blank screen, which was shown for 100 ms. The total feedback, which indicated the overall outcome of a task block (including bonuses), was always presented at the end of the respective task block (for 1800 ms) and was followed by a grey blank screen of 100 ms before the next task block began or a change in context was indicated. Failure to implement the superordinate task goal or failure to answer within 900 ms led to the termination of the current task block and zero outcomes (goal failure; see also above). Points acquired in the experiment were cashed into real money. Subjects could receive up to 30 €, which were added to the general reimbursement for participation.

Figure 2: Graphical depiction of the DRD task. Subjects got first presented the cue (either the desire context (left) or the reason context (right)) and then had to react on the shown colors as priory trained.

Emotional face-matching task (“Hariri”): The face-matching task aimed at activating face processing regions (e.g., fusiform face area), limbic regions (e.g., amygdala) and prefrontal regions (Hariri et al. 2002). In the active condition, subjects viewed gray-scale images of fearful or angry faces (Ekman 1992), in the control condition they viewed geometric shapes (circles and ellipsoids). In each trial, three items were presented. A target image was located at the top, two further images on the left and right side at the bottom, whereby one of these images was identical to the target image. Every subject was first instructed outside the scanner to this task. Inside the MR scanner, the participant had to indicate which of these two images was identical to the target image by pressing a corresponding button on an MRI-compatible response pad. The task was set up as block design, with six face and shape trials, respectively, per block. Blocks had a duration of 44 s (faces) and 32 s (shapes), respectively. Five shapes blocks and four faces blocks were presented in alternating order, starting with a shapes block (Figure 3). Blocks were separated by short inter-block-intervals (1.5–5.5 s). The paradigm lasted 6 min 14 s.

Figure 3: Graphical depiction of the emotional face-matching task. Subjects viewed in blocks either gray-scale images of fearful or angry faces (block length 44 s) or geometric shapes (block length 32 sec). Each block started with a short introductory screen (“Geometrische Formen” = geometrical shapes; “Gesichter” = faces).

Theory of Mind (ToM) task: The ToM task showed cartoons in which different social situations were depicted (see Figure 3). It aimed to activate the ToM network relevant for social cognition since a dysfunction of the ToM network activated by this task is associated with a genetic risk variant for BD and in relatives of patients with BD (Walter et al. 2011). The paradigm has been described in detail elsewhere (Walter et al. 2011).

The ToM task consisted of two alternately presented conditions: a ToM condition and a control condition. Both conditions were presented eight times each. They started with an introduction (6.5 s) followed by a cartoon story consisting of three consecutive pictures (7.5 s per picture) (Figure 4). All pictures were free of direct signs of the characters’ emotions (e.g., facial expressions). The subject was instructed to either evaluate in each picture the affective state of the protagonist (ToM condition) or to count the number of living beings (control condition). In the second and third picture, the subject had to indicate by a button press whether the affective state was better, equal, or worse compared to the previous picture (ToM condition) or whether the number of living beings was higher, equal or lower compared to the previous picture (ToM condition) (button press was carried out with the right hand; index finger = worse affective state / less living beings, middle finger = equal state / living beings, ring finger = better affective state, more living beings).

Figure 4: Graphical depiction of the ToM task. Each trial consisted of an introduction describing the respective task and a cartoon story consisting of three consecutive pictures. In the ToM condition, the subjects had to judge how the affective state is changed in pictures 2 and 3 compared to the previous picture. In the control condition, the subject has to judge whether the number of living beings is changed.

2.3 MRI data acquisition parameters

All MRI data sets were acquired at 3T MR scanners with different hardware and software configurations. An overview of the different scanner types and the receive coils is given in Table 5. Pulse sequences were first implemented and tested at the University of Marburg (which was the coordinating center). Parameters were subsequently standardized across all sites to the extent permitted by each platform. Before the study started, scientists from the coordinating center Marburg performed site visits at all participating centers to check the adherence to the study protocol and to train the measurement procedure. Additionally, a “traveling subject” was also measured during these site-visits.

The MRI scanning protocol consisted of a T1-weighted high-resolution anatomical image, four echo-planar imaging (EPI) sequences sensitive to blood oxygen level dependent (BOLD) contrast for fMRI measurements, a field map and an EPI measurement for quality assessment (see 2.2). The MRI sequences were always performed in the same fixed order. The T1-weighted image was used to align the

measurement volumes of all the following EPI sequences. Slices were positioned transaxially parallel to the anterior-posterior commissural line (AC-PC), based on the smallest measurement volume of the sequences. This alignment was then copied to all the other sequences. Special care was taken that both temporal lobes were always included inside the measured volume. A complete list of all MRI parameters is presented for each MR scanner in Appendix 1.

Site	Manufacturer	MRI scanner type	Field	Receive coil
Berlin	Siemens	Tim Trio	3 Tesla	20 channels
Bochum	Philips	Achieva	3 Tesla	32 channels
Dresden	Siemens	Tim Trio	3 Tesla	12 channels
Frankfurt	Siemens	Trio	3 Tesla	8 channels
Göttingen	Siemens	Tim Trio	3 Tesla	12 channels
Hamburg	Siemens	Skyra	3 Tesla	32 channels
Heidelberg	Siemens	Tim Trio	3 Tesla	12 channels
Marburg	Siemens	Tim Trio	3 Tesla	12 channels
Tübingen	Siemens	Prisma	3 Tesla	20 channels

Table 5: List of MR scanners (manufacturer, scanner types, field strength) and receive coils at each study site.

2.4 MRI Quality assessment: Phantom data

Large, longitudinal, multi-center MRI studies require comprehensive quality assurance (QA) protocols to assess the general quality of the acquired data, to indicate potential malfunctions in the scanning equipment and to evaluate inter-site differences that need to be accounted for in subsequent analyses. Several examples of QA protocols for MRI data are described in the literature, mostly in the context of large-scale multicenter studies (for an overview, see Glover et al. (2012), Van Horn and Toga (2009)). In the *BipoLife* study, MR scanner characteristics were assessed by the regular measurement of a MRI phantom. The phantom was a 23.5 cm long and 11.1 cm-diameter cylindrical plastic vessel (Rotilabo, Carl Roth GmbH + Co. KG, Karlsruhe, Germany) filled with a mixture of 62.5 g agar and 2000 ml distilled water. Phantoms were built at the University of Marburg and sent to each participating center. All study sites, therefore, used the same type of phantom.

Phantom data were acquired after the measurement of each subject. The alignment of the phantom was lengthwise, i.e., parallel to the main scanner axis, and at the center of the head coil. The measurement volume was manually centered at the phantom with a slice direction perpendicular to the phantom body (see Vogelbacher et al. (2018) for a graphical depiction). We developed a QA program that focused on the temporal stability of the MRI data. Temporal stability is in particular important for fMRI measurements in

which MR scanners are typically highly stressed. Therefore, the MRI phantom was measured with an EPI sequence. The same sequence parameters were chosen for the resting-state measurement. Also, the same scanner-specific reconstruction methods were employed.

A variety of QA parameters can be calculated from phantom data, for instance, geometric accuracy, contrast resolution, ghosting level, spatial uniformity and signal-to-noise ratio (see Figure 5 for an example). The QA protocol used statistics that are described in detail in previous publications of our research groups (Vogelbacher et al. 2018). The phantom data were analyzed using the *LAB-QA2GO* software package (Vogelbacher et al. 2019). A detailed analysis of the QA phantom data, in particular concerning the effect of different MR scanners and the impact of hardware and software changes, is described elsewhere (Vogelbacher et al., in preparation; but also see Vogelbacher et al. (2018) for a similar analysis on data from a bi-center MRI study performed by our research groups).

Figure 5: Signal-to-Noise Ratio (SNR) values of phantom measurements of three different BipoLife sites across time. The MR scanner of Marburg (blue) shows stable values but a lower SNR value compared to Hamburg (black) or Tübingen (purple). The SNR values of Tübingen and Hamburg are in general higher but have higher variations over time.

2.5 Data storage

After an initial quality check by staff from the local study sites, all MRI data (except for project B2) was transferred via the Internet in raw Digital Imaging and Communications in Medicine (*DICOM*) format to the coordinating center Marburg. Project B2 was an add-on project to an ongoing separate multicenter, double-blind, randomized controlled trial. The project-specific data policy did not allow data collection in Marburg. MRI data for this project was therefore stored on DVDs and sent to the University of Heidelberg. According to the study protocol of B2, the University of Heidelberg is responsible for the data storage and data analysis.

At the University of Marburg, the data was transformed from the *DICOM* format to Brain Imaging Data Structure (*BIDS*) format using *heudiconv* (Gorgolewski et al. 2016). *Heudiconv* is a flexible *DICOM* converter for organizing brain imaging data into structured directory layouts (Halchenko et al. 2020). The *BIDS* format has been developed to standardize data storage for neuroimaging experiments. This format enables the usage of different *BIDS*-Apps to analyze the imaging data with standardized software packages. It also enables other scientists to access the data for different analysis approaches.

Each data set was checked for completeness, both with regard to the MRI data and the corresponding log files. A frequent error source was the wrong alignment of the measurement volume in the functional measurements. Therefore, all MRI data was checked promptly to be able to give early feedback to the respective study sites. A first quality control was performed using the *BIDS*-App *MRIQC* (Magnetic Resonance Imaging Quality Control, (Esteban et al. 2017)). *MRIQC* assesses both structural T1-weighted MR images and BOLD-images of the brain by calculating a set of quality measures from each image.

MRIQC uses 14 Image Quality Metrics that characterize each image in 56 features. The tool also includes a visual reporting system to manually investigate potential quality issues in single subjects.

3. Discussion

The research consortium *BipoLife* is a German-wide network of university centers that aims to investigate bipolar disorder, in particular concerning its early recognition, reliable diagnosis, rational treatment and prognosis (Ritter et al. 2016). The network comprised several clinical and neuroscientific studies. MRI data were acquired in three projects. Data acquisition started in 2015 and ended in December 2020. The same neuroimaging protocol was used in all projects.

One strength of the present study is the careful implementation of a comprehensive multicenter study protocol including a QA protocol for assessing the general quality of the compiled MRI data. Acquiring neuroimaging data over several years from up to nine different sites requires, among others, the harmonization of the acquisition protocol, the standardization of paradigms and the implementation of regular quality control procedures. Modern MR scanners have in general good technical quality, for instance high SNR, sufficient image homogeneity and good image contrast. Image characteristics, however, will inevitably change over the course of a study. This is in particular a challenge for fMRI data because functional signal changes are typically just in the order of about 1–5 % of the raw signal intensity. The temporal stability of MRI acquisitions is therefore important to differentiate between MR signal changes associated with an altered disease status (e.g. by the effect of a psychotherapeutic intervention) and signal changes caused by alterations of the MR scanner system (Friedman and Glover 2006). It has been previously argued that the implementation of QA methods has become one key benchmark in the evaluation of the overall quality of large-scale imaging studies (Van Horn and Toga 2009). The documented adherence to the QA protocol will help to guide both clinicians and researchers to evaluate the quality, impact, and relevance of the study to the patient-level.

In previous large-scale multicenter studies, malfunctions of the MR scanners were, if at all, often only detected after the study was finished, for instance during a retrospective analysis of phantom data (see Friedman and Glover (2006) for an example). In the *BipoLife* consortium, the implemented QA procedures monitored MR scanner performance promptly, defined benchmark characteristics and were able to assess the impact of hard- and software changes in scanner settings. This information can also be implemented in subsequent MRI data analyses, for instance by excluding data from specific subjects or imaging sites or by implementing corrections for site-specific effects.

In the present description of the study protocol, we deliberately refrained from specifying more detailed data analysis pipelines. On the one hand, these analyses have been already described in previous publications of the participating research groups (e.g., (Dannlowski et al. 2012; Diekhof and Gruber 2010; Kessler et al. 2020; Meller et al. 2020; Nenadic et al. 2015; Trost et al. 2014; Walter et al. 2011)). On the other hand, they will be most likely adapted to the specific research questions. All MRI data (except for project B2 due to issues of protection of data privacy) was stored centrally in the recently developed BIDS

format and had been checked for completeness and overall quality. It can therefore be analyzed without extensive preparatory work.

Another strength of the overall study results from the combination of well-planned clinical projects with the extensive deep-phenotyping MRI approach. Project A1 is the first investigation of a help-seeking cohort of at-risk persons for BD. Its major strengths are the large sample size and the high number of assessment points during the particularly vulnerable phase of disease development and potential conversion to BD (at least five assessments over a period of at least two years; see Pfennig et al. (2020) for an in-depth description of the study design of A1). Clinical and MRI data can be combined for instance to test whether neuroimaging data will improve the prediction of whether or not an individual will develop BD. The MRI data can be ultimately used to improve evidence-based guidelines for early detection and interventions for people at high risk for BD. Project A2 is to our knowledge the biggest multicenter randomized controlled trial (RCT) in the field of psychotherapy in bipolar disorders to date (see Stamm et al. (2020) for a detailed study description). By comparing two different treatment approaches in the early stage of bipolar disorder, it is possible to assess to what extent a specific, cognitive behavioral therapy could be superior to a supportive, experience- and emotion-focused intervention. Clinical and MRI data can now be combined to identify potential neurobiological predictors for (successful) response to psychotherapeutic interventions in bipolar disorder. Project B2 is an add-on imaging project for an already ongoing multicenter, double-blind RCT. It investigates the additional effect of lithium in affectively ill patients with acute suicidality, in addition to “treatment as usual” (see Lewitzka et al. (2015) or a description of the study protocol). The MRI data can be used to identify neuroimaging markers that predict successful anti-suicidal treatment with lithium. A potential limitation of this project is the relatively low number of recruited subjects.

In summary, the present article described the MRI study protocol of the *BipoLife* project. On the one hand, it provided the technical background necessary for an in-depth understanding of the subsequent data analyses. On the other hand, it outlined how clinical and neuroimaging data can be combined to further understand the mechanisms underlying BD.

4. Abbreviations

AC-PC	- anterior-posterior commissure
ADHD	- Attention Deficit Hyperactivity Disorder
BD	- Bipolar disorder (BD)
BIDS	-Brain Imaging Data Structure
BOLD	- blood oxygen level dependent
DICOM	- Digital Imaging and Communications in Medicine

DRD	- desire-reason dilemma
EPI	- echo-planar imaging
FEST therapy	- “Fördernde, Emotionsfokussierte, Supportive Psychotherapie”, supportive, self-directed therapy
fMRI	- functional magnetic resonance imaging
MR	- magnetic resonance
MRI	- magnetic resonance imaging
MRIQC	- Magnetic Resonance Imaging Quality Control
QA	- quality assurance
RCT	- randomized controlled trial
SEKT psychotherapy	- “Spezifische Emotional-Kognitive Psychotherapie”, short-term emotional-cognitive psychotherapy
SNR	- Signal-to-Noise ratio
TAU	- Treatment as usual
ToM	- Theory-of-Mind
TPP2	- translational imaging platform

5. Declarations

Ethics approval and consent to participate

Project A1 was approved by all local ethics committees and is registered with www.clinicaltrials.gov as [NCT02456545](https://www.clinicaltrials.gov/ct2/show/study/NCT02456545). Project A2 was approved by all local ethics committees and is registered with www.clinicaltrials.gov as [NCT02506322](https://www.clinicaltrials.gov/ct2/show/study/NCT02506322). Project B2 obtained ethics approval via the central ethics committee for pharmaceutical studies (BfArM). It is registered with www.clinicaltrials.gov as [NCT02039479](https://www.clinicaltrials.gov/ct2/show/study/NCT02039479). All participants provided written informed consent after comprehensive information about study aims and procedures.

Availability of data and materials

Data sharing is not applicable to this article as it is a study protocol and no datasets were analyzed at this stage of the study process. When publishing the data, the datasets used and/or analyzed during the study will be available from the corresponding author on reasonable request.

Competing interests

AP has received speakers honoraria and travel support from Janssen and Lundbeck.

CV, JS, VS, MHAB, IF, PSR, FB, CHA, LR, KEE, JT, OG, GJ, VF, CM, MH, AP, SM, AR, DG, UD, TK, MB, AJ did not state any conflict of interest.

Funding

The BIOLIFE consortium is funded by the Federal Ministry of Education and Research (BMBF, grant numbers 01EE1404A-H). The translational neuroimaging platform TPP2 was funded by the BMBF grant 01EE1404E.

Authors' contributions

CV: central coordination of all imaging aspects within the consortium, particularly quality management and centralized analysis of imaging data, collecting data and revision of manuscript.

JS: critical revision of the manuscript

VS: drafting and revision of the manuscript, creating MRI phantoms, investigator of study BipoLife A1

MHAB: drafting and revision of the manuscript

IF: drafting and revision of the manuscript

PSR: critical revision of manuscript and assistance in the central coordination of the described projects;

FB: conception of the fMRI platform in BipoLife A2 and revision of manuscript.

CHA: conception of the fMRI platform in BipoLife A2 and revision of manuscript.

LR: coordination of study BipoLife B2, data collection, DRD-specific quality management and centralized analyses (BipoLife A1, A2 and B2), and revision of manuscript.

KEE: DRD-specific quality management and centralized analyses (BipoLife A1 and A2), and revision of manuscript.

JT: DRD-specific quality management and centralized analyses (BipoLife A1 and A2), and revision of manuscript.

OG: conception, design and principal investigator of study BipoLife B2, and revision of manuscript.

GJ: central role in securing funds, design of the consortium and deputy head to the central coordinator of the consortium, and revision of manuscript.

VF: collecting data and revision of manuscript

CM: conception, design and coordination of all electrophysiological aspects within the consortium (in particular BipoLife A1), and revision of manuscript.

MH: principal investigator of A2, local organizer and supervisor, revision of manuscript

AP: conception, design and principal investigator of study BipoLife A1, and revision of manuscript.

SM: coordination of BipoLife A1, BipoLife A2 and BipoLife TPP2 at the Frankfurt site, revision of manuscript

AR: conception, design and co-principal investigator of central database and biobank management within the consortium (BipoLife TPP1), and revision of manuscript.

DG: critical revision of the manuscript

UD: critical revision of the manuscript

TK: central coordination of all imaging aspects within the consortium, particularly quality management and centralized analysis of imaging data, and revision of manuscript.

MB: conception and design of the consortium as a whole, central coordination of all projects within the consortium and revision of manuscript.

AJ: central coordination of all imaging aspects within the consortium, particularly quality management and centralized analysis of imaging data, and revision of manuscript.

6. References

Axelson D, Goldstein B, Goldstein T, Monk K, Yu H, Hickey MB, et al. Diagnostic Precursors to Bipolar Disorder in Offspring of Parents With Bipolar Disorder: A Longitudinal Study. *AJP. American Psychiatric Publishing*; 2015 Mar 3;172(7):638–46.

Dannlowski U, Stuhrmann A, Beutelmann V, Zwanzger P, Lenzen T, Grotegerd D, et al. Limbic Scars: Long-Term Consequences of Childhood Maltreatment Revealed by Functional and Structural Magnetic Resonance Imaging. *Biological Psychiatry*. 2012 Feb 15;71(4):286–93.

Diekhof EK, Gruber O. When desire collides with reason: Functional interactions between anteroventral prefrontal cortex and nucleus accumbens underlie the human ability to resist impulsive desires. *Journal of Neuroscience*. 2010;30(4):1488–93.

Diekhof EK, Keil M, Obst KU, Henseler I, Dechent P, Falkai P, et al. A functional neuroimaging study assessing gender differences in the neural mechanisms underlying the ability to resist impulsive desires. *Brain Research*. 2012 Sep 14;1473:63–77.

Duffy A. The Nature of the Association Between Childhood ADHD and the Development of Bipolar Disorder: A Review of Prospective High-Risk Studies. *AJP. American Psychiatric Publishing*; 2012 Dec 1;169(12):1247–55.

Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. *The British Journal of Psychiatry. Cambridge University Press*; 2014 Feb;204(2):122–8.

Ekman P. An Argument for Basic Emotions. *Cognition and Emotion*. 1992. p. 169–200.

Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: Advancing the automatic prediction of image quality in MRI from unseen sites. Bernhardt BC, editor. *PLOS ONE*. 2017 Sep 25;12(9):e0184661.

Friedman L, Glover GH. Report on a multicenter fMRI quality assurance protocol. *Journal of Magnetic Resonance Imaging. Wiley Subscription Services, Inc., A Wiley Company*; 2006 Jun 1;23(6):827–39.

Glover GH, Mueller BA, Turner JA, Van Erp TGMM, Liu TT, Greve DN, et al. Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. *Journal of Magnetic Resonance Imaging. Wiley Subscription Services, Inc., A Wiley Company*; 2012 Jul 1;36(1):39–54.

Gorgolewski KJ, Auer T, Calhoun VD, Craddock RC, Das S, Duff EP, et al. The brain imaging data structure, a format for organizing and describing outputs of neuroimaging experiments. *Scientific Data. Nature Publishing Group*; 2016 Jun 21;3(1):160044.

Halchenko Y, Goncalves M, Visconti di Oleggio Castello, Ghosh S, Hanke M, Salo T, et al. nipy/heudiconv v0.8.0 [Internet]. Zenodo; 2020 [cited 2021 Feb 10]. Available from: <https://zenodo.org/record/3760062#.YCO8UGhKhPY>

Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR. The Amygdala Response to Emotional Stimuli: A Comparison of Faces and Scenes. *NeuroImage*. 2002;17(1):317–23.

Kessler R, Schmitt S, Sauder T, Stein F, Yüksel D, Grotegerd D, et al. Long-Term Neuroanatomical Consequences of Childhood Maltreatment: Reduced Amygdala Inhibition by Medial Prefrontal Cortex. *Front. Syst. Neurosci. [Internet]. Frontiers*; 2020 [cited 2021 Feb 10];14. Available from: <https://www.frontiersin.org/articles/10.3389/fnsys.2020.00028/full>

Lewitzka U, Jabs B, Fülle M, Holthoff V, Juckel G, Uhl I, et al. Does lithium reduce acute suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus Treatment As Usual (TAU) in patients with suicidal major depressive episode. *BMC Psychiatry*. 2015 May 19;15(1):117.

McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The Heritability of Bipolar Affective Disorder and the Genetic Relationship to Unipolar Depression. *Archives of General Psychiatry*. 2003 May 1;60(5):497–502.

Meller T, Schmitt S, Ettinger U, Grant P, Stein F, Brosch K, et al. Brain structural correlates of schizotypal signs and subclinical schizophrenia nuclear symptoms in healthy individuals. *Psychological Medicine*. Cambridge University Press; 2020 May 27;1–10.

Murray CJL, editor. *The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020; summary*. Cambridge: Harvard School of Public Health [u.a.]; 1996.

Nenadic I, Dietzek M, Schönfeld N, Lorenz C, Gussew A, Reichenbach JR, et al. Brain structure in people at ultra-high risk of psychosis, patients with first-episode schizophrenia, and healthy controls: a VBM study. *Schizophrenia Research*. 2015 Feb 1;161(2):169–76.

Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. *Neuropsychologia*. 1971 Mar 1;9(1):97–113.

Pfennig A, Leopold K, Martini J, Boehme A, Lambert M, Stamm T, et al. Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). *International Journal of Bipolar Disorders*. 2020 Jul 1;8(1):22.

Pfennig A, Ritter PS, Höfler M, Lieb R, Bauer M, Wittchen H-U, et al. Symptom characteristics of depressive episodes prior to the onset of mania or hypomania. *Acta Psychiatrica Scandinavica*. 2016;133(3):196–204.

Ritter PS, Bempohl F, Gruber O, Hautzinger M, Jansen A, Juckel G, et al. Aims and structure of the German Research Consortium BipoLife for the study of bipolar disorder. *International Journal of Bipolar Disorders*. 2016 Nov 21;4(1):26.

Stamm TJ, Zwick JC, O'Malley G, Sondergeld L-M, Hautzinger M. Adjuvant psychotherapy in early-stage bipolar disorder: study protocol for a randomized controlled trial. *Trials*. 2020 Oct 13;21(1):845.

Trost S, Diekhof EK, Zvonik K, Lewandowski M, Usher J, Keil M, et al. Disturbed Anterior Prefrontal Control of the Mesolimbic Reward System and Increased Impulsivity in Bipolar Disorder. *Neuropsychopharmacology*. Nature Publishing Group; 2014 Jul;39(8):1914–23.

Van Horn JD, Toga AW. Multisite neuroimaging trials. *Current Opinion in Neurology*. 2009;22(4):370–8.

Vogelbacher C, Bopp MHA, Schuster V, Herholz P, Jansen A, Sommer J. LAB-QA2GO: A Free, Easy-to-Use Toolbox for the Quality Assessment of Magnetic Resonance Imaging Data. *Frontiers in Neuroscience*. Frontiers; 2019 Jul 3;13:688.

Vogelbacher C, Möbius TWD, Sommer J, Schuster V, Dannlowski U, Kircher T, et al. The Marburg-Münster Affective Disorders Cohort Study (MACS): A quality assurance protocol for MR neuroimaging data. *NeuroImage*. 2018;172:450–60.

Walter H, Schnell K, Erk S, Arnold C, Kirsch P, Esslinger C, et al. Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. *Molecular Psychiatry*. Nature Publishing Group; 2011 Apr;16(4):462–70

Figures




Figure 1

Study overview. Left: After inclusion in the clinical studies A1, A2 and B2, respectively, subjects received the option to additionally participate in the MRI assessments (“MRI information”). If they were eligible and consented, they were introduced to each task outside the MR scanner (“MRI training”). Right: The MRI measurement consisted of a localizer scan, a structural T1-weighted image, a resting state fMRI

sequence, three task-based fMRI paradigms (DRD task, “Hariri” task and ToM task) and a field map. The DRD task was divided into two sessions.




Figure 2

Graphical depiction of the DRD task. Subjects got first presented the cue (either the desire context (left) or the reason context (right)) and then had to react on the shown colors as priory trained.




Figure 3

Graphical depiction of the emotional face-matching task. Subjects viewed in blocks either gray-scale images of fearful or angry faces (block length 44 s) or geometric shapes (block length 32 sec). Each block started with a short introductory screen (“Geometrische Formen” = geometrical shapes; “Gesichter” = faces).




Figure 4

Graphical depiction of the ToM task. Each trial consisted of an introduction describing the respective task and a cartoon story consisting of three consecutive pictures. In the ToM condition, the subjects had to judge how the affective state is changed in pictures 2 and 3 compared to the previous picture. In the control condition, the subject has to judge whether the number of living beings is changed.




Figure 5

Signal-to-Noise Ratio (SNR) values of phantom measurements of three different BipoLife sites across time. The MR scanner of Marburg (blue) shows stable values but a lower SNR value compared to Hamburg (black) or Tübingen (purple). The SNR values of Tübingen and Hamburg are in general higher but have higher variations over time.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalMaterialBipoLifeStudyProtocol.docx](#)